Literature DB >> 1899803

Activation of human monocyte-derived macrophages by interferon gamma is accompanied by increase of poly(ADP-ribose) polymerase activity.

G Berton1, C Sorio, C Laudanna, M Menegazzi, A Carcereri De Prati, H Suzuki.   

Abstract

We have investigated poly(ADP-ribosyl)ation processes in human monocyte-derived macrophages and the effect of the activating cytokine, interferon gamma (IFN-gamma) on these processes. IFN-gamma was shown to increase the activity of poly(ADP-ribose) polymerase in human macrophages. A 2-3-fold enhancement of poly(ADP-ribose) polymerase activity was observed after 3-4 h of incubation with IFN-gamma, whose effects were dose-dependent and maximal at 20-50 U/ml. Staining with anti-poly(ADP-ribose) antibodies and purification of ADP-ribosylated nuclear proteins by affinity chromatography over boronate agarose showed that enhancement of poly(ADP-ribose) polymerase activity by IFN-gamma was accompanied by accumulation of poly(ADP-ribose) polymers in nuclear proteins. The effects of IFN-gamma on poly(ADP-ribose) polymerase activity were not due to an enhanced accumulation of the message for the enzyme, indicating that the activation of the enzyme activity was due to post-transcriptional modifications. IFN-gamma was shown to induce DNA strand breaks in human macrophages. This phenomenon followed the same time-course and was evident with the same doses of IFN-gamma that increased poly(ADP-ribose) polymerase activity. Since poly(ADP-ribose) polymerase is known to require DNA nicks for its activity, the capability of IFN-gamma to induce DNA strand breaks can explain its effects on poly(ADP-ribosyl)ation processes.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1899803     DOI: 10.1016/0167-4889(91)90228-p

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  8 in total

1.  Inhibitors of poly(ADP-ribose) polymerase-1 suppress transcriptional activation in lymphocytes and ameliorate autoimmune encephalomyelitis in rats.

Authors:  Alberto Chiarugi
Journal:  Br J Pharmacol       Date:  2002-11       Impact factor: 8.739

2.  Poly(ADP-ribose) polymerase-1 dependence of stress-induced transcription factors and associated gene expression in glia.

Authors:  Hyo Chol Ha; Lynda D Hester; Solomon H Snyder
Journal:  Proc Natl Acad Sci U S A       Date:  2002-02-19       Impact factor: 11.205

3.  Modulation of poly(ADP-ribose) polymerase during neutrophilic and monocytic differentiation of promyelocytic (NB4) and myelocytic (HL-60) leukaemia cells.

Authors:  M Bhatia; J B Kirkland; K A Meckling-Gill
Journal:  Biochem J       Date:  1995-05-15       Impact factor: 3.857

4.  Nicotinamide inhibits nitric oxide synthase mRNA induction in activated macrophages.

Authors:  C Pellat-Deceunynck; J Wietzerbin; J C Drapier
Journal:  Biochem J       Date:  1994-01-01       Impact factor: 3.857

5.  Poly(ADP-ribose) polymerase inhibition with HYDAMTIQ reduces allergen-induced asthma-like reaction, bronchial hyper-reactivity and airway remodelling.

Authors:  Laura Lucarini; Alessandro Pini; Elisabetta Gerace; Roberto Pellicciari; Emanuela Masini; Flavio Moroni
Journal:  J Cell Mol Med       Date:  2014-01-20       Impact factor: 5.310

6.  A Study into the ADP-Ribosylome of IFN-γ-Stimulated THP-1 Human Macrophage-like Cells Identifies ARTD8/PARP14 and ARTD9/PARP9 ADP-Ribosylation.

Authors:  Hideyuki Higashi; Takashi Maejima; Lang Ho Lee; Yukiyoshi Yamazaki; Michael O Hottiger; Sasha A Singh; Masanori Aikawa
Journal:  J Proteome Res       Date:  2019-03-21       Impact factor: 4.466

Review 7.  The impact of PARPs and ADP-ribosylation on inflammation and host-pathogen interactions.

Authors:  Anthony R Fehr; Sasha A Singh; Catherine M Kerr; Shin Mukai; Hideyuki Higashi; Masanori Aikawa
Journal:  Genes Dev       Date:  2020-02-06       Impact factor: 11.361

8.  Indoleamine 2,3-Dioxygenase Activity Increases NAD+ Production in IFN-γ-Stimulated Human Primary Mononuclear Cells.

Authors:  Ross S Grant
Journal:  Int J Tryptophan Res       Date:  2018-01-08
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.